Welcome to the fifth installment in this series surveying business and regulatory issues in the Oregon psilocybin program. Today I will cover intellectual property considerations for Oregon psilocybin businesses. My law firm has written and presented many hundreds of times on intellectual property and controlled substances over the years. Mostly, this material focused on the
A recently published letter (“Letter”) indicates that the Biden administration is preparing for the approval of psychedelic drugs and MDMA to treat mental illness and PTSD. This type of federal agency correspondence would have been unimaginable five or six years ago. Things are changing fast! There are well-known potential health benefits of MDMA and psychedelics
Friday was a great day for psychedelics. More generally, Friday was a great day for science and medicine, the rule of law and rational inquiry. This is because the DEA backed down on its clumsy attempt to ban five more psychedelic substances (tryptamines), which it had moved to place on Schedule I of the federal
A statewide psychedelics decriminalization bill that’s been on pause for almost a year was recently set for a legislative hearing next month. This is huge news for California psychedelics advocates, even if we don’t have a ton of information on what is likely to happen just yet. In 2021, California State Senator Scott Wiener introduced
Since January 1, 2021, the Oregon Health Authority (OHA) has engaged in a two-year development phase, creating regulations based on Ballot Measure 109. There are five subcommittees covering different aspects of the emerging psilocybin industry including research, health equity, manufacturing, training, and licensing. In this post, we will cover the most recent Research Subcommittee meeting
Earlier this year, Utah passed a law that will directly impact ketamine clinics. The new law is entitled “Anesthesia and sedation requirements – Unprofessional conduct – Whistleblower protection.” Ut. St. § 58-1-510. The new law is effective as of May 4, 2022, but the implementing regulations have been passed or implemented yet. We believe that
The Oregon Psilocybin Advisory Board (OPAB) was established by Measure 109 and is responsible for making recommendations to the Oregon Health Authority (OHA) for psilocybin services in Oregon. OPAB has met monthly since March of 2021, and the last monthly meeting was set for June 22, 2022. After that, OPAB will meet every two months. In a
In November 2020, Oregon voters passed Measure 109, which directs the Oregon Health Authority (OHA) to license and regulate the manufacture, delivery, sale, and administration of psilocybin. Licensing is set to kick off in early 2023. Things remain on track. We’ve written a lot about Measure 109 here on the Psychedelics Law Blog, including: 1)
On May 26, 2022, the Oregon Health Authority (OHA) announced it received a legal memorandum from the Oregon Department of Justice (ODOJ). The legal memorandum (memo) addresses the Oregon Psilocybin Services Program and discussed the Entheogenic Framework. The Entheogenic Framework is a document created by Jon Dennis, an attorney in Oregon. It is a set
We often receive questions from ketamine clinics regarding who must obtain a DEA registration to dispense controlled substances. There are two candidates to consider – the healthcare providers who work at the clinic and the clinic itself. Often, there is a misconception about whether a clinic needs to hold a DEA registration. We wrote about
